Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Nov 12 - Nov 17
OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities
It is even used medically to support heart function in certain conditions (heart failure, angina)
A potentially novel target to treat obesity and type 2 diabetes is nicotinamide-N-methyltransferase (NNMT), a cytosolic enzyme with newly identified roles in cellular metabolism and energy homeostasis
An occludin-focal adhesion kinase protein complex at the blood-testis barrier: a study using the cadmium model
US$ 23.48
US$ 23.44
US$ 25.58
US$ 28.16
US$ 20.30
US$ 24.25
US$ 26.14
